Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajay Tuli

Interventional Cardiology Tucson, AZ Medical Doctor

NPI 1093793267 CMS profile 49826

1238 W Orange Grove Rd, Suite 102, Tucson, AZ 85704

Open in the dashboard

General payments

$14,312

941 records reported · program years 2019–2025

Research payments

$46,230

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$690,824 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Ajay Tuli of Tucson, AZ is reported in the CMS Open Payments database as having received $14,312 across 941 general payments and $46,230 in research payments paid to them. Separately, studies naming them as principal investigator received $690,824 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,019 64
2024 General $1,927 114
2024 Research $46,230 1
2023 General $1,985 119
2022 General $1,993 160
2021 General $1,427 159
2020 General $1,293 122
2019 General $4,669 203

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajay Tuli
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ajay Tuli were reported at $1,019. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ajay Tuli Interventional Cardiology median Middle half National median
2019 $4,669 $1,097 $329–$3,048 $163
2020 $1,293 $473 $161–$1,480 $114
2021 $1,427 $677 $233–$1,827 $132
2022 $1,993 $978 $333–$2,724 $149
2023 $1,985 $1,136 $382–$2,986 $160
2024 $1,927 $1,181 $395–$3,326 $164
2025 $1,019 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $1,983 86 payments
  2. Biotronik Inc. $1,518 6 payments
  3. Novartis Pharmaceuticals Corporation $1,413 184 payments
  4. Abbott Laboratories $1,340 191 payments
  5. Canon Medical Systems USA, Inc. $1,085 3 payments
  6. Pfizer Inc. $927 76 payments
  7. Janssen Pharmaceuticals, Inc $860 135 payments
  8. Actelion Pharmaceuticals US, Inc. $686 56 payments
  9. E.R. Squibb & Sons, L.L.C. $496 36 payments
  10. Amgen Inc. $479 43 payments
  11. Other $3,525 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,044 936 payments
  2. Travel and Lodging $2,243 4 payments
  3. Grant $25 1 payment
Products named General payments · program years 2019–2025
  1. Impella $1,912 85 payments
  2. XARELTO $870 137 payments
  3. OPSUMIT $679 55 payments
  4. LEQVIO $669 43 payments
  5. ELIQUIS Cardiovascular;Metabolic Disease $524 47 payments
  6. UPTRAVI $477 31 payments
  7. VERQUVO $473 24 payments
  8. ENTRESTO $465 113 payments
  9. ELIQUIS Cardiovascular $457 32 payments
  10. VYNDAQEL $428 33 payments
  11. Other $6,128 437 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $46,230 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

16,097

Median for Interventional Cardiology: 2,236

Drug cost

$6,725,667

Median for Interventional Cardiology: $380,412

Branded share of claims

29%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 56 $2,029,980
Eliquis Apixaban Brand 1,272 $1,734,123
Xarelto Rivaroxaban Brand 975 $1,285,427
Entresto Sacubitril/Valsartan Brand 458 $646,387
Farxiga Dapagliflozin Propanediol Brand 229 $295,642
Repatha Sureclick Evolocumab Brand 169 $202,354
Jardiance Empagliflozin Brand 111 $158,914
Multaq Dronedarone Hcl Brand 32 $67,739
Praluent Pen Alirocumab Brand 34 $34,466
Vascepa Icosapent Ethyl Brand 28 $27,141

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$412,660

Of which drugs: $82

Medicare patients

1,991

Average age 78

Services billed

7,389

940 women, 1,051 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 43%
Atrial fibrillation 37%
Chronic kidney disease 31%
Diabetes 25%
Heart failure 24%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 880 $82

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$301 — —
Repatha
$180 169 —
Kerendia
$156 12 —
ENTRESTO
$122 458 —
ELIQUIS
$95 1,272 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

942 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record